Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
CONCLUSIONS: The Gilteritinib-based regimen shows a high and sustained therapeutic effect with minimal adverse effects, and provides a valuable experience for further evaluation in EMR APL patients.PMID:38095349 | DOI:10.1080/16078454.2023.2293496 (Source: Hematology)
Source: Hematology - December 14, 2023 Category: Hematology Authors: Chun-Xiao Hou Yu Chen Shan-Hao Liu Yi-Zhi Jiang Dong-Ping Huang Su-Ning Chen Source Type: research
Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
CONCLUSION: In summary, the VEN combination regimen is effective for the treatment of newly diagnosed AML patients in the real world despite VEN dose reductions .PMID:38095287 | DOI:10.1080/16078454.2023.2293512 (Source: Hematology)
Source: Hematology - December 14, 2023 Category: Hematology Authors: Jingying Cui Xuexing Chen Chunfang Li Qiong Yan Guolin Yuan Source Type: research
Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
This study is the first to report an AUL patient treated with the "VA" scheme and achieved CR. Our result preliminarily suggested the effectiveness and safety of the "VA" scheme in AUL treatment, but validation is required in more clinical samples. The "VA" scheme provides a new treatment option for AUL patients and deserves further clinical promotion.PMID:38095304 | DOI:10.1080/16078454.2023.2293494 (Source: Hematology)
Source: Hematology - December 14, 2023 Category: Hematology Authors: Yu Cui Ruihua Mi Lin Chen Lin Wang Dongbei Li Xudong Wei Source Type: research
Mortality among US veterans with a physician-documented diagnosis of pyruvate kinase deficiency
Hematology. 2024 Dec;29(1):2290746. doi: 10.1080/16078454.2023.2290746. Epub 2023 Dec 14.ABSTRACTReal-world studies of pyruvate kinase (PK) deficiency and estimates of mortality are lacking. This retrospective observational study aimed to identify patients with PK deficiency and compare their overall survival (OS) to that of a matched cohort without PK deficiency. Patients with ≥1 diagnosis code related to PK deficiency were selected from the US Veterans Health Administration (VHA) database (01/1995-07/2019); patients with a physician-documented diagnosis were included (PK deficiency cohort; index: date of first diagnosi...
Source: Hematology - December 14, 2023 Category: Hematology Authors: Erin Zagadailov Hanny Al-Samkari Audra N Boscoe Bryan McGee Sherry Shi Dendy Macaulay Lizheng Shi Viviana Garcia-Horton Source Type: research
Cognitive-behavioral stress management relieves anxiety, depression, and post-traumatic stress disorder in parents of pediatric acute myeloid leukemia patients: a randomized, controlled study
CONCLUSION: CBSM reduces anxiety, depression, and PTSD in parents of pediatric AML patients.PMID:38095309 | DOI:10.1080/16078454.2023.2293498 (Source: Hematology)
Source: Hematology - December 14, 2023 Category: Hematology Authors: Li Wang Hui Duan Hongmei Zuo Zhongyu Wang Shuili Jiao Yanli Liu Huihui Li Jie Chen Source Type: research
Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
CONCLUSIONS: The Gilteritinib-based regimen shows a high and sustained therapeutic effect with minimal adverse effects, and provides a valuable experience for further evaluation in EMR APL patients.PMID:38095349 | DOI:10.1080/16078454.2023.2293496 (Source: Hematology)
Source: Hematology - December 14, 2023 Category: Hematology Authors: Chun-Xiao Hou Yu Chen Shan-Hao Liu Yi-Zhi Jiang Dong-Ping Huang Su-Ning Chen Source Type: research
Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
CONCLUSION: In summary, the VEN combination regimen is effective for the treatment of newly diagnosed AML patients in the real world despite VEN dose reductions .PMID:38095287 | DOI:10.1080/16078454.2023.2293512 (Source: Hematology)
Source: Hematology - December 14, 2023 Category: Hematology Authors: Jingying Cui Xuexing Chen Chunfang Li Qiong Yan Guolin Yuan Source Type: research
Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
This study is the first to report an AUL patient treated with the "VA" scheme and achieved CR. Our result preliminarily suggested the effectiveness and safety of the "VA" scheme in AUL treatment, but validation is required in more clinical samples. The "VA" scheme provides a new treatment option for AUL patients and deserves further clinical promotion.PMID:38095304 | DOI:10.1080/16078454.2023.2293494 (Source: Hematology)
Source: Hematology - December 14, 2023 Category: Hematology Authors: Yu Cui Ruihua Mi Lin Chen Lin Wang Dongbei Li Xudong Wei Source Type: research
Mortality among US veterans with a physician-documented diagnosis of pyruvate kinase deficiency
Hematology. 2024 Dec;29(1):2290746. doi: 10.1080/16078454.2023.2290746. Epub 2023 Dec 14.ABSTRACTReal-world studies of pyruvate kinase (PK) deficiency and estimates of mortality are lacking. This retrospective observational study aimed to identify patients with PK deficiency and compare their overall survival (OS) to that of a matched cohort without PK deficiency. Patients with ≥1 diagnosis code related to PK deficiency were selected from the US Veterans Health Administration (VHA) database (01/1995-07/2019); patients with a physician-documented diagnosis were included (PK deficiency cohort; index: date of first diagnosi...
Source: Hematology - December 14, 2023 Category: Hematology Authors: Erin Zagadailov Hanny Al-Samkari Audra N Boscoe Bryan McGee Sherry Shi Dendy Macaulay Lizheng Shi Viviana Garcia-Horton Source Type: research
Cognitive-behavioral stress management relieves anxiety, depression, and post-traumatic stress disorder in parents of pediatric acute myeloid leukemia patients: a randomized, controlled study
CONCLUSION: CBSM reduces anxiety, depression, and PTSD in parents of pediatric AML patients.PMID:38095309 | DOI:10.1080/16078454.2023.2293498 (Source: Hematology)
Source: Hematology - December 14, 2023 Category: Hematology Authors: Li Wang Hui Duan Hongmei Zuo Zhongyu Wang Shuili Jiao Yanli Liu Huihui Li Jie Chen Source Type: research
Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
CONCLUSIONS: The Gilteritinib-based regimen shows a high and sustained therapeutic effect with minimal adverse effects, and provides a valuable experience for further evaluation in EMR APL patients.PMID:38095349 | DOI:10.1080/16078454.2023.2293496 (Source: Hematology)
Source: Hematology - December 14, 2023 Category: Hematology Authors: Chun-Xiao Hou Yu Chen Shan-Hao Liu Yi-Zhi Jiang Dong-Ping Huang Su-Ning Chen Source Type: research
Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis
CONCLUSION: Our real-world data demonstrate superior OS rates of HMA + VEN when compared to IC, HMC or BSC, with a favourable side effect profile with regard to transfusion needs or hospitalization days.Abbreviations: AML, acute myeloid leukaemia; BCL2, B-cell leukaemia/lymphoma-2; BSC, best supportive care; CR, complete response; Cri, complete response with incomplete haematologic regeneration; FLT3, Fms Related Receptor Tyrosine Kinase 3; EKOS, Ethikkomission Ostschweiz; ELN, European Leukaemia Net; HMA, hypomethylating agent; IC, intensive chemotherapy; IDH, Isocitratdehydrogenase; LDAC, low-dose Cytarabine; NCCN, Natio...
Source: Hematology - December 11, 2023 Category: Hematology Authors: Tabea Sutter Marcus Schittenhelm Thomas Volken Thomas Lehmann Source Type: research
Adult presentation of ornithine transcarbamylase deficiency: a possible cause of hyperammonemia after high-dose chemotherapy and stem cell transplantation
Hematology. 2023 Dec;28(1):2265187. doi: 10.1080/16078454.2023.2265187. Epub 2023 Oct 5.ABSTRACTHyperammonemia is a rare and often fatal complication following the conditioning therapy in autologous and allogeneic stem cell transplant recipients. It is characterized by anorexia, vomiting, lethargy and coma without any other apparent cause. The diagnosis is often delayed because symptoms can be subtle and ammonia is usually not included among the routine analyzes. Previous reports have not identified the molecular mechanisms behind hyperammonemia in stem cell transplant recipients. Urea cycle disorders (UCDs) are inborn err...
Source: Hematology - December 11, 2023 Category: Hematology Authors: Galina Tsykunova Erle Kristensen Asbj ørg Stray-Pedersen Øyvind Bruserud Ida Wiig S ørensen Øystein Bruserud Tor Henrik Anderson Tvedt Source Type: research
Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis
CONCLUSION: Our real-world data demonstrate superior OS rates of HMA + VEN when compared to IC, HMC or BSC, with a favourable side effect profile with regard to transfusion needs or hospitalization days.Abbreviations: AML, acute myeloid leukaemia; BCL2, B-cell leukaemia/lymphoma-2; BSC, best supportive care; CR, complete response; Cri, complete response with incomplete haematologic regeneration; FLT3, Fms Related Receptor Tyrosine Kinase 3; EKOS, Ethikkomission Ostschweiz; ELN, European Leukaemia Net; HMA, hypomethylating agent; IC, intensive chemotherapy; IDH, Isocitratdehydrogenase; LDAC, low-dose Cytarabine; NCCN, Natio...
Source: Hematology - December 11, 2023 Category: Hematology Authors: Tabea Sutter Marcus Schittenhelm Thomas Volken Thomas Lehmann Source Type: research
Adult presentation of ornithine transcarbamylase deficiency: a possible cause of hyperammonemia after high-dose chemotherapy and stem cell transplantation
Hematology. 2023 Dec;28(1):2265187. doi: 10.1080/16078454.2023.2265187. Epub 2023 Oct 5.ABSTRACTHyperammonemia is a rare and often fatal complication following the conditioning therapy in autologous and allogeneic stem cell transplant recipients. It is characterized by anorexia, vomiting, lethargy and coma without any other apparent cause. The diagnosis is often delayed because symptoms can be subtle and ammonia is usually not included among the routine analyzes. Previous reports have not identified the molecular mechanisms behind hyperammonemia in stem cell transplant recipients. Urea cycle disorders (UCDs) are inborn err...
Source: Hematology - December 11, 2023 Category: Hematology Authors: Galina Tsykunova Erle Kristensen Asbj ørg Stray-Pedersen Øyvind Bruserud Ida Wiig S ørensen Øystein Bruserud Tor Henrik Anderson Tvedt Source Type: research
